Skip to main content
Harold Brem, MD, General Surgery, Newark, NJ

Harold Brem MD

General Surgery•Newark, NJ

Professor of Surgery Rutgers New Jersey Medical School Chief, Division of Wound Healing and Regenerative Medicine Department of Surgery

Join to View Full Profile

  • 201 Lyons AveNewark, NJ 07112

  • Phone+1 973-854-4335

Dr. Brem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Brem's Full ProfileAlready have an account?

Summary

  • Dr. Harold Brem is a highly experienced, board-certified general surgeon with over 27 years in the field, specializing in wound healing and regenerative medicine. He is a Professor of Surgery at Rutgers New Jersey Medical School and the Chief of the Division of Wound Healing & Regenerative Medicine at Newark Beth Israel Medical Center. Dr. Brem is a pioneer in academic wound healing and clinical research, applying his findings to treat complex wounds. He leads a team of gifted surgeons, residents, and medical students to deliver the best outcomes and to provide comprehensive treatment for a range of wounds and skin disorders, including hidradenitis suppurativa, decubitus ulcers, diabetic foot ulcers, limb salvage, necrotizing fasciitis, sepsis related to wounds, and emergency surgery related to these complicated cases.

    Dr. Brem’s key contributions include developing evidence-based protocols for diabetic foot ulcers, which have been adopted globally; identifying genes that impair wound healing; pioneering the use of regenerative medicine like stem cells and human fibroblast keratinocytes for wound healing; and creating innovative surgical debridement techniques guided by molecular markers to optimize healing. His approach to patient care is evidence-based and patient-centered, combining extensive clinical expertise with ongoing research to improve outcomes. He founded a unique, all-in-one wound care service that includes a basic science lab, inpatient and outpatient centers, regenerative medicine, and 24/7 surgery, making his practice a comprehensive model for wound healing.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalResidency, Surgery, 1987 - 1995
  • Harvard Medical School
    Harvard Medical SchoolResearch Fellow in Surgery, Wound Healing Research, 1989 - 1992
  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineClass of 1987

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2017 - 2025
  • NY State Medical License
    NY State Medical License 1995 - 2025
  • Surgery
    American Board of Surgery Surgery

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Developing Strategies for Effective Debridement in Patients for Venous Leg UlcersNational Institute of Arthritis and Musculoskeletal and Skin Diseases2019–2023
  • Cellular Mechanism of Healing of Chronic WoundsGemstone Biotherapeutics Inc.2016–2017
  • A Prospective clinical outcome study of the Use of Type 1 Purified Collagen Matrix (Puraply) in the Treatment of Chronic WoundsOrganogenesis2016–2017
  • Clinical Research Center to Decrease Limb Amputation Rate in People with DiabetesNIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2011–2017
  • A randomized, double-blind, multicenter, superiority, placebo-controlled phase 3 study of pexiganan acetate cream 0.8% applied twice daily for 14 days in the treatment of adults with mild infections oDipexium Pharmaceuticals DPX 3062015
  • Evaluate the safety, tolerability and efficacy of cureXcell as an adjunct to good wound care measures in treating lower extremity chronic ulcers in adults w/diabetesMacro Cure/ MC- 102 Core, follow up and open label2013
  • Wound EMR to Decrease Limb Amputations in Persons with DiabetesDepartment of Health and Human Services Agency for Healthcare Research and Quality2010–2013
  • Emotional Stress and Wound Healing in Diabetes (clinical trial)NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2011–2012
  • Development of the Cellular Biomarker for Diabetic Foot UlcersNIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2009–2012
  • Wound EMR to Decrease Limb Amputations in Persons with DiabetesAHRQ, Agency for Healthcare Research and Quality2010–2011
  • Diabetic Foot and Pressure Ulcer Databank- Admin SupplementNIH, National Library of Medicine (NLM)2009–2010
  • Experimental Model for Pressure Ulcers in Human Skin: The Role of the Extracellular Matrix and AgingNIH, National Institute of Aging (NIA)2008–2010
  • Establishment of a clinical research & translational wound centerHelen and Martin Kimmel Foundation2008–2010
  • Randomized, Double-Blind, Placebo-Controlled, Single- and Double-Dose Comparator Arm (Standard Care), Multi-center Phase 2b Study of Typical GAM501 (Ad5PDGF-B/bovine type I collagen gel) in the TreatmTissue Repair Company2007–2008
  • Epidermal Genes and Their Regulators in Wound HealingNational Institute of Nursing Research (NINR)2003–2008
  • Wounds, Local Angiogenic Therapy for Diabetic UlcersNIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2002–2006
  • Local Sustained Release with the Angiogenic Molecule VEGF to Treat Experimental Diabetic WoundsAmerican Diabetes Association2002–2005
  • Local Angiogenic Gene Therapy with VEGF to Treat Diabetic UlcersNIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2002–2004
  • Pathophysiology and Treatments for Pressure UlcersUnited Spinal Association1998–2004
  • An Open Prospective Clinical Outcome to Measure the Effect of an Alternating Pressure Air Mattress Upon the Closure Rates of Sub-Dermal Pressure UlcersPegasus/ Edgerton Ltd.2000–2002
  • A double-blind, placebo-controlled, parallel group, randomized study evaluating the effect of Regranex (becaplermin) gel versus placebo gel in the treatment of full-thickness pressure ulcersJohnson and Johnson1998–2001
  • A prospective, multicenter, randomized, single-masked, controlled, clinical investigation of Dermagraft in patients with plantar diabetic foot ulcersAdvanced Tissue Sciences1999–2000

Committees

  • Member, Wound Collaborative Committee
  • Associate editor, Surgical Technology International, Wound Healing Section
  • Committee Member, Newark Beth Israel Medical Center: Surgical Executive Committee, Medical Executive Committee, Ethics, and Surgery-Quality Committee

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Harold Brem, Dr. Harold Brem, MD, Dr. H Brem